Form 4: Cingulate CCO Granted 30,000 Stock Options

Cingulate Inc.'s Chief Commercial Officer, Bryan Wade Downey, was granted 30,000 stock options with an exercise price of $3.8.

Summary

• Bryan Wade Downey, Chief Commercial Officer of Cingulate Inc. (CING), was granted 30,000 stock options.
• The options have an exercise price of $3.8 per share.
• The grant date for these options was November 3, 2025.
• The options will vest over time, with 25% vesting on the one-year anniversary of the grant date (November 3, 2026), and the remaining shares vesting in substantially equal monthly installments over the subsequent 36 months.
• The options have an expiration date of November 3, 2035.
• Following this transaction, Bryan Wade Downey beneficially owns 30,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's interests with long-term shareholder value creation and promotes executive retention. This is a routine compensation event and does not reflect on operational performance.

Positives

• The grant of 30,000 stock options to the Chief Commercial Officer aligns executive incentives with shareholder interests, encouraging long-term performance.
• The vesting schedule promotes executive retention and sustained focus on company growth over several years.

Future Outlook

The vesting schedule for the granted stock options indicates a long-term incentive structure designed to align the Chief Commercial Officer's interests with the company's future performance and growth over the next several years.

Industry Context

The grant of stock options to a key executive is a standard practice in the biotechnology and pharmaceutical industries, commonly used to attract, retain, and incentivize top talent by aligning their financial interests with the long-term success and shareholder value of the company.

Comparison to Industry Standards

• Executive equity grants, such as stock options, are a common component of compensation packages across the industry, similar to practices at comparable biotech firms aiming to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with long-term shareholder value.
• Employees: This is a standard executive compensation practice and does not directly impact general employees as mentioned in the filing.

Next Steps

• The stock options will begin vesting on November 3, 2026, with subsequent monthly vesting installments over the following 36 months.

Key Dates

Keywords

Cingulate Inc., CING, Form 4, Bryan Wade Downey, Chief Commercial Officer, Stock Options, Equity Grant, Executive Compensation, Insider Transaction